Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Fiche publication
Date publication
août 2023
Journal
Journal of thrombosis and haemostasis : JTH
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MANGIN Pierre
Tous les auteurs :
Alenazy FO, Harbi MH, Kavanagh DP, Price J, Brady P, Hargreaves O, Harrison P, Slater A, Tiwari A, Nicolson PLR, Connolly DL, Kirchhof P, Kalia N, Jandrot-Perrus M, Mangin PH, Watson SP, Thomas MR
Lien Pubmed
Résumé
Aspirin and platelet P2Y inhibitors, such as ticagrelor, suboptimally inhibit microvascular thrombosis during ST-elevation myocardial infarction (STEMI). GPIIb/IIIa inhibitors may further inhibit this, but cause excessive bleeding. We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in haemostasis.
Mots clés
Acute coronary syndromes, GPVI, antiplatelet therapy, atherosclerotic plaque, platelets
Référence
J Thromb Haemost. 2023 08 2;: